Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 14

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 14
---
 As a foreign private issuer, we are not subject
to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations
that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, although
we report our financial results on a quarterly basis, we will not be required to issue quarterly reports, proxy statements that comply
with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed
as that required of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file our annual reports
with the SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies. We also present
financial statements pursuant to IFRS instead of pursuant to U.S. generally accepted accounting principles. Furthermore, although the
members of our management and supervisory boards will be required to notify the Israeli Securities Authority, of certain transactions
they may undertake, including with respect to our common shares, our officers, directors and principal shareholders will be exempt from
the requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained in Section
16 of the Exchange Act. As a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated
under the Exchange Act. In addition, as a foreign private issuer, we are permitted, and follow certain home country corporate governance
practices instead of those otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. These exemptions and leniencies
reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting
companies.

We may take advantage of these
exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as
more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)
the majority of our executive officers or directors are U.S. citizens or residents; (ii) more than 50% of our assets are located in the
United States; or (iii) our business is administered principally in the United States.

Both foreign private issuers
and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules